Skip to Content
Merck
CN

936391

Fmoc-Gly-Gly-OH

≥95%

Synonym(s):

2-[2-([[(9H-Fluoren-9-yl)methoxy]carbonyl]amino)acetamido]acetic acid, N-9-Fluorenylmethoxycarbonylglycylglycine, N-Fluorenylmethoxycarbonylglycylglycine, N-[(9H-Fluoren-9-ylmethoxy)carbonyl]glycylglycine (ACI), Glycine, N-[(9H-fluoren-9-ylmethoxy)carbonyl]glycyl- (9CI, ACI), Glycine, N-[N-[(9H-fluoren-9-ylmethoxy)carbonyl]glycyl]- (ZCI)

Sign In to View Organizational & Contract Pricing.

Select a Size


About This Item

Empirical Formula (Hill Notation):
C19H18N2O5
CAS Number:
Molecular Weight:
354.36
UNSPSC Code:
12352106
NACRES:
NA.22
MDL number:
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

InChI key

FBKUOPULLUJMOC-UHFFFAOYSA-N

SMILES string

O=C(OCC1C=2C=CC=CC2C=3C=CC=CC31)NCC(=O)NCC(=O)O

InChI

1S/C19H18N2O5/c22-17(20-10-18(23)24)9-21-19(25)26-11-16-14-7-3-1-5-12(14)13-6-2-4-8-15(13)16/h1-8,16H,9-11H2,(H,20,22)(H,21,25)(H,23,24)

assay

≥95%

form

powder or crystals

color

white to off-white

storage temp.

2-8°C

Quality Level

Application

Fmoc-Gly-Gly-OH is a lysosomally cleavable linker used in construction of antibody-drug conjugates (ADC & Bioconjugation).

Other Notes

Chemical Biology Tools

http://pubs.rsc.org/en/Content/ArticleLanding/2011/MB/C0MB00074D#!divAbstract

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Alain Beck et al.
Nature reviews. Drug discovery, 16(5), 315-337 (2017-03-18)
Antibody-drug conjugates (ADCs) are one of the fastest growing classes of oncology therapeutics. After half a century of research, the approvals of brentuximab vedotin (in 2011) and trastuzumab emtansine (in 2013) have paved the way for ongoing clinical trials that

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service